|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09997 KANGJI MEDICAL
Nominal 
5.910 0.000 (0.000%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 458,413 | 13.584% | 926,023 | 786,367 | 690,263 | 511,490 |
| Cost of Sales | (95,290) | 16.443% | (184,824) | (151,120) | (127,337) | (80,020) |
| Gross Profit | 363,123 | 12.857% | 741,199 | 635,247 | 562,926 | 431,470 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 842 | -- | (1,064) | 1,054 | (614) | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (5,868) | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 327,733 | 20.809% | 588,771 | 563,144 | 534,497 | 310,075 | |
| Taxation | (52,047) | 23.966% | (136,476) | (101,970) | (77,708) | (50,925) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 10,161 | -61.164% | 51,726 | 17,561 | 0 | (8,854) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 285,847 | 11.895% | 504,021 | 478,735 | 456,789 | 250,296 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (62,016) | 49.584% | (89,575) | (68,128) | (33,092) | (11,735) |
| Depreciation & Amortisation | 14,179 | -12.270% | 32,954 | 21,631 | 11,860 | 8,204 |
| Directors' Emoluments | -- | -- | 9,302 | 7,734 | 7,756 | 8,204 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 24.390 | 11.727% | 43.080 | 39.630 | 37.310 | 26.270 |
| DPS (cts) | 0.000 | -- | 140.000 | 18.450 | 14.610 | 3.702 |
| Dividend Payout Ratio (%) | -- | -- | 324.977% | 46.556% | 39.158% | 14.093% |
| Cash flow per share ($) | -- | -- | 0.359 | 0.264 | 0.356 | 0.232 |
| NBV per share ($) | 1.945 | -- | 2.999 | 2.766 | 2.617 | 2.345 |
| Remarks: | Real time quote last updated: 15/11/2024 09:31 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 285,847,000 |
| %Change | 11.895% |
| EPS / (LPS) | RMB 0.244 |
| NBV Per Share (¥) | RMB 1.945 |